#Lalpathlabs valuation 🧵
History :
Sales history :
2011 : 240 Cr
2020 : 1300 Cr
Trend : 20.64% CAGR growth in sales.
Profit history :
2011 : 30 Cr
2020 : 230 Cr
Trend : 25.39% CAGR growth in profits.
The company spends almost equal amount on its personnel as it spends on raw materials.
Current 12M trend shows a rise in volumes as more and more people opt for blood tests. Profit margin has also risen by 2%. This will add to the long term compounding.
Verdict : Strong BUY.
Future projection :
2030 EPS : 170 rs/share
2030 CMP : 8117
Lalpath Labs is a comparatively cleaner proxy play on the healthcare theme, rather than buying debt laden companies like Fortis or Apollo Hospital.
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.